VIVES is a multi-sector fund that invests in projects with a positive societal impact
iTeos Therapeutics targets the tumor microenvironment to boost immune cell efficiency in cancer eradication.
Immunotherapy is a revolutionary approach to cancer treatment that aims to educate the...
Keemotion has developed a motion detection technology. Their proprietary software offers a complete solution for coaches, leagues and broadcasters. Thanks to Keemotion, your organization produces...
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
Pierre Drion, business angel :
"For almost 20 years I have been passionate about what is called biotech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
David Frenay, CEO Emolytics :
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
"It has been great to partner early on with VIVES fund. VIVES fund helped us to finance the company, challenged us in our thinking to push us further in our thinking, provided us with regular input,...
Mont Saint-Guibert, Belgium – October 28, 2021 – Novadip Biosciences, a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs,
Louvain-la-Neuve, 22 October 2021 – VOCSens raises €2.5 million in seed funding in order to industrialise its gas microsensors. The objective? The aim is to commercialise its micro gas sensors in the
Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine fever (ASF). In the